GP

Girij Pal Singh

Active Director Director DIN 11155605
DIN 11155605 First appointment Jun 2025
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since Jun 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Girij Pal Singh

Data last updated:

Girij Pal Singh is a Director at Aeim Therapeutics Private Limited (since 2025) and Director at Athena Generics Private Limited (since 2025).

DIN 11155605
Primary Designation Director
First Appointment 16 Jun 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Aeim Therapeutics Private Limited U70200PN2025PTC248009
Director04 Nov 20252025Active
Athena Generics Private Limited U72100PN2025PTC243009
Director16 Jun 20252025Active

Board colleagues of Girij Pal Singh

Directorship timeline

Open interactive timeline →
Aeim Therapeutics Private Limited
Athena Generics Private Limited
Premium access

Shareholding and investment profile for Girij Pal Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Girij Pal Singh

Girij Pal Singh currently holds 2 directorships: Aeim Therapeutics Private Limited (Director, since 04 Nov 2025); Athena Generics Private Limited (Director, since 16 Jun 2025).

Girij Pal Singh was first appointed on 16 Jun 2025 as Director at Athena Generics Private Limited.

The current boards of Girij Pal Singh's companies include Archana Singh (Aeim Therapeutics Private Limited), Debashish Datta (Athena Generics Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available